“Smoldering multiple myeloma” (SMM) is a blood and bone marrow disorder which can lead to multiple myeloma, a deadly cancer.

SAN DIEGO -- The risk of progression from smoldering multiple myeloma to symptomatic disease decreased by 50% in patients treated with the anti-CD38 monoclonal antibody daratumumab (Darzalex ...

Early interventions with daratumumab reduced progression and prolonged overall survival rate in patients with high-risk ...

Daratumumab significantly reduced progression risk in smoldering multiple myeloma, especially in high-risk patients, with a 64% reduction compared to active monitoring. The treatment did not ...

Daratumumab, an anti-CD38 monoclonal antibody, has been approved for the treatment of multiple myeloma. Data are needed regarding the use of daratumumab for high-risk smoldering multiple myeloma ...

A new treatment is showing promise for people with high-risk smoldering multiple myeloma (SMM). This precancerous condition can progress to active multiple myeloma, a type of blood cancer.

A new treatment is showing promise for people with high-risk smoldering multiple myeloma (SMM). This precancerous condition can progress to active multiple myeloma, a type of blood cancer.

SAN DIEGO — The multiple myeloma (MM) drug daratumumab (Darzalex), an anti-CD38 monoclonal antibody, dramatically reduced progression to active MM or death in patients with high-risk smoldering ...

ROCHESTER, Minn. — A new treatment is showing promise for people with high-risk smoldering multiple myeloma (SMM). This precancerous condition can progress to active multiple myeloma ...

A second study showed improvement in biomarkers linked to progression of smoldering myeloma to the frank disease state in patients who consumed a plant-based, fiber-rich diet. Both studies were ...

“Smoldering multiple myeloma” (SMM) is a blood and bone marrow disorder which can lead to multiple myeloma, a deadly cancer. Detecting the condition can be a challenge, because those living ...

Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window SAN DIEGO -- The risk of progression from smoldering multiple myeloma to symptomatic disease decreased by 50% in ...